Toshi Taniguchi, MD, PhD
Fred Hutchinson Cancer Research Center
Secondary Mutations of BRCA1/2 in BRCA 1/2 Mutated Ovarian Cancer with Primary Platinum Resistance
Platinum compounds are key drugs for the treatment of ovarian cancer and often help patients gain initial remission. However, some patients do not respond, called “primary platinum resistance.” To understand why this happens, we will analyze ovarian tumors with primary platinum resistance in patients with BRCA1/2 mutations. Our study may clarify why the resistance occurs and eventually lead to the establishment of a strategy to overcome this problem.